Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • AChR
    (2)
  • Potassium Channel
    (2)
  • Others
    (8)
Filter
Search Result
Results for "oxybutynin" in TargetMol Product Catalog
  • Inhibitor Products
    10
    TargetMol | Activity
  • Isotope products
    1
    TargetMol | inventory
rac-Desethyl Oxybutynin (hydrochloride)
T3780181039-77-2
rac-Desethyl oxybutynin is an active metabolite of the muscarinic acetylcholine receptor (mAChR) antagonist oxybutynin .1,2,3rac-Desethyl oxybutynin is formed from oxybutynin by the cytochrome P450 (CYP) isoform CYP3A4.2It binds to mAChRs in isolated rat bladder, submaxillary gland, heart, and colon with Kivalues of 5.38, 3.12, 16, and 5.59 nM, respectively.rac-Desethyl oxybutynin (0.4 and 0.8 mg/kg) reduces micturition pressure in rats.3
  • $198
35 days
Size
QTY
Oxybutynin
T1049L5633-20-5
Oxybutynin (Ditropan) is a synthetic anticholinergic agent that is used for treatment of urinary incontinence and overactive bladder syndrome.
  • $47
In Stock
Size
QTY
Oxybutynin R-isomer HCl
T712361207344-05-5
Oxybutynin R-isomer , also known as Aroxybutynin, is a muscarinic receptor antagonist. Aroxybutynin is the optically avtice inhibitor of proliferation and supresses gene expression in bladder smooth muscle cells. Oxybutynin exerts direct antispasmodic effect on smooth muscle and inhibits the muscarinic action of acetylcholine on smooth muscle. It exhibits one-fifth of the anticholinergic activity of atropine on the rabbit detrusor muscle, but four to ten times the antispasmodic activity. No blocking effects occur at skeletal neuromuscular junctions or autonomic ganglia (antinicotinic effects).
  • $1,520
6-8 weeks
Size
QTY
(R)-Oxybutynin
T61309119618-21-2
(R)-Oxybutynin (Aroxybutynin) is an orally active muscarinic receptor antagonist, which exhibits antimuscarinic, antispasmodic, and anticholinergic activity. This compound, being the (R)-isomer of Oxybutynin, competitively antagonizes Carbachol-induced contractions. It is particularly useful in researching neurogenic bladder dysfunction-related incontinence [1] [2] [3].
  • $2,140
6-8 weeks
Size
QTY
Oxybutynin chloride
T10491508-65-2
Oxybutynin chloride (Oxybutynin HCl) is an anticholinergic medication used to relieve urinary and bladder difficulties. It competitively antagonizes the M1, M2, and M3 subtypes of the muscarinic acetylcholine receptor.
  • $35
In Stock
Size
QTY
N-Desethyl Oxybutynin-d5 hydrochloride
T121441173018-49-9
N-Desethyl Oxybutynin D5 hydrochloride is the the active metabolite Oxybutynin, is deuterium labeled N-Desethyl Oxybutynin hydrochloride.
  • $525
7-10 days
Size
QTY
Esoxybutynin Chloride
T71889230949-16-3
Esoxybutynin Chloride is (S)-enantiomer of oxybutynin. Esoxybutynin Chloride exerts antimuscarinic properties. Racemic oxybutynin is used clinically to treat urinary incontinence. Sepracor was developing (S)-oxybutynin, a single-isomer version of Alza's Ditropan (racemic oxybutynin), a muscarinic acetylcholine receptor antagonist, as a potential treatment for urinary incontinence.
  • $1,520
6-8 weeks
Size
QTY
Esoxybutynin Free Base
T71268119618-22-3
Esoxybutynin Free Base is (S)-enantiomer of oxybutynin. Esoxybutynin Free Base exerts antimuscarinic properties. Racemic oxybutynin is used clinically to treat urinary incontinence. Sepracor was developing (S)-oxybutynin, a single-isomer version of Alza's Ditropan (racemic oxybutynin), a muscarinic acetylcholine receptor antagonist, as a potential treatment for urinary incontinence.
  • $1,520
6-8 weeks
Size
QTY
AGN-190383
T71234120755-15-9
AGN-190383 is a phospholipase inhibitor with topical anti-inflammatory activity.
  • $1,520
6-8 weeks
Size
QTY
AH-9700 fumarate
T29742L337359-08-7
AH-9700 fumarate is a the salt form of AH-9700 and a biochemical which has been shown to improve abnormal frequent urination cystitis in a manner different from that of oxybutynin.
  • $1,520
Backorder
Size
QTY